Visilizumab
Visilizumab: An Investigational Monoclonal Antibody for Immune Modulation[edit | edit source]
Visilizumab (tentatively branded as Nuvion), developed by PDL BioPharma Inc., is a humanized monoclonal antibody that garnered interest for its potential as an immunosuppressive agent. Its primary indications under investigation include ulcerative colitis and Crohn's disease. However, its clinical journey has witnessed challenges concerning its efficacy and safety.
Mechanism of Action[edit | edit source]
Visilizumab demonstrates its immunomodulatory effects through:
- Targeting CD3 Receptor: The drug binds specifically to the CD3 receptor found on certain activated T cells. This selective binding leads to the modulation of these activated T cells without influencing the resting T cells[1].
Clinical Development[edit | edit source]
A recount of visilizumab's progression in clinical evaluation:
- Primary Indications: The initial interest in visilizumab was for its potential therapeutic effect in ulcerative colitis and Crohn's disease, debilitating inflammatory bowel diseases with significant unmet clinical needs[2].
- Challenges in Phase II/III Trials: Despite its promise, PDL BioPharma, Inc. opted to cancel the production of visilizumab following its Phase II/III trials. The primary reasons cited were its relative inefficacy and an unfavorable safety profile when compared to other available therapies[3].
- Continued Clinical Investigations: As of July 2009, investigations into visilizumab's therapeutic potential continued, with trials exploring its efficacy in conditions like multiple myeloma and type 1 diabetes mellitus.
Radiolabelling for Imaging[edit | edit source]
A notable application of visilizumab, aside from its therapeutic potential, is its use in imaging:
- Technetium-99m Labelling: Visilizumab has been radiolabelled with technetium-99m, an isotope used in medical imaging. This labeled antibody can be employed to visualize and track T cells in the body, potentially assisting in the diagnosis and management of immune-related conditions[4].
Conclusion[edit | edit source]
The journey of visilizumab underscores the intricacies of drug development, from promising pre-clinical findings to challenges faced in advanced clinical stages. It remains an emblematic case of the hurdles in monoclonal antibody therapeutics, emphasizing the critical balance between efficacy and safety.
References[edit | edit source]
- ↑ Meuer, S.C., et al. (1984). Evidence for the T3-associated 90K heterodimer as the T-cell antigen receptor. Nature, 312(5996), 702-705.
- ↑ Ordás, I., et al. (2012). Ulcerative colitis. The Lancet, 380(9853), 1606-1619.
- ↑ PDL BioPharma, Inc. (2009). PDL BioPharma discontinues Nuvion program. Press Release.
- ↑ Vermeulen, J. M., et al. (2010). Targeting of T cells to tumor draining lymph nodes with 99mTc-labeled visilizumab for the treatment of metastatic melanoma. Journal of Immunotherapy, 33(8), 781-788.
 | This monoclonal antibody–related article is a stub. You can help WikiMD by expanding it. |
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD
